• 1
    Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration and immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977; 252: 35783581.
  • 2
    Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977; 252: 35823586.
  • 3
    Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003; 55: 12931302.
  • 4
    Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther. 2004; 26: 9911025.
  • 5
    Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther. 2002; 24: 13631383.
  • 6
    Stathopoulos GP, Dimou E, Stathopoulos J, Xynotroulas J. Therapeutic administration of pegfilgrastim instead of prophylactic use. Anticancer Res. 2005; 25: 24452448.
  • 7
    Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004; 10: 12351244.
  • 8
    Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol modified adenosine deaminase. N Engl J Med. 1987; 316: 589596.
  • 9
    Morar AS, Schrimsher JL, Chavez MD. PEGylation of proteins: a structural approach. Biopharm Int. 2006; 19: 3442.
  • 10
    Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002; 54: 459476.
  • 11
    Harris JM, Zalipsky S. Introduction to chemistry and biological applications of poly(ethylene glycol). In: HarrisJM, ZalipskyS, eds. Poly(Ethylene Glycol) Chemistry and Biological Applications. Washington, DC: ACS Publications; 1997: 113.
  • 12
    Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bionconj Chem. 1995; 6: 150165.
  • 13
    Dreborg S, Akerblom E. Immunotherapy with monomethoxypolyethylene glycol modified allergens. Crit Rev Ther Drug Carrier Syst. 1990; 6: 315365.
  • 14
    Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev. 2003; 55: 217250.
  • 15
    Francis GE, Fisher D, Delgado C., Malik F, Gardiner A, Neale D. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol. 1998; 68: 118.
  • 16
    Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst. 1992; 9: 249304.
  • 17
    Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev. 2002; 28( Suppl A): 1316.
  • 18
    Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco. 1999; 54: 497516.
  • 19
    Monfardini C, Veronese FM. Stabilization of substances in circulation. Bioconjug Chem. 1998; 9: 418450.
  • 20
    Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev. 2002; 54: 587606.
  • 21
    Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev. 2002; 54: 505530.
  • 22
    Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol. 1984; 74: 3639.
  • 23
    Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol. 1983; 70: 124131.
  • 24
    Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett. 2005; 10: 3747.
  • 25
    Armstrong JK, Meiselman HJ, Wenby RB, Fisher TC. In vivo survival of poly(ethylene glycol)-coated red blood cells in the rabbit. Blood. 2003; 102: 94A.
  • 26
    Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem. 2000; 11: 258266.
  • 27
    Cheng TL, Cheng CM, Chen BM, et al. Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug Chem. 2005; 16: 12251231.
  • 28
    Leger RM, Arndt P, Garratty G, Armstrong JK, Meiselman HJ, Fisher TC. Normal donor sera can contain antibodies to polyethylene glycol (PEG). Transfusion. 2001; 41: 29S.
  • 29
    Armstrong JK, Leger R, Wenby RB, Meiselman HJ, Garratty G, Fisher TC. Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood. 2003; 102: 556A.
  • 30
    Garratty G. Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Trans Med Rev. 2004; 18: 245256.
  • 31
    Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield, MS. Control of hyperuricemia in subjects with refractory gout, and induction of an antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006; 8: R12.
  • 32
    Hempel G, Lanvers-Kaminsky C, Muller HJ, Wurtwein G, Boos J. A population pharmacokinetic model describing the activity-time-course of PEG-asparaginase in children. Blood. 2004; 11: 751A.
  • 33
    Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar™) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000; 110: 379384.
  • 34
    Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Onc/Hematol. 1998; 28: 97113.
  • 35
    Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Phramacokinet. 2005; 44: 367393.
  • 36
    Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000; 14: 22052222.
  • 37
    Vieira Pinheiro JP, Lanvers C, Wurthwein G, et al. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma. 2002; 43: 19111920.
  • 38
    Lanvers C, Viera Pinheiro JP, Hempel G, Wurthwein G, Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem. 2002; 309: 117126.
  • 39
    General laboratory methods. In: Vengelen-TylerV, ed. AABB Technical Manual, 13th ed. Bethesda: American Association of Blood Banks; 1999: 646.
  • 40
    Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993; 11: 17801786.
  • 41
    Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996; 32A: 15441550.
  • 42
    Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006; 91: 2431.
  • 43
    Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06–97. Pediatr Blood Cancer. 2006; 46: 1825.
  • 44
    Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration in mice. J Pharm Sci. 1994; 83: 601606.
  • 45
    van der Eijk AA, Vrolijk JM, Haagmans BL. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med. 2006; 354: 13231324.
  • 46
    Fisher TC, Armstrong JK, Wenby RB, Meisleman HJ, Leger R, Garratty G. Isolation and identification of a human antibody to poly(ethylene glycol). Blood. 2003; 102: 559A.